Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193290 | 1.00 | APP (0.46) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL37545 | 0.97 | APP (0.48) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL30782568 | 0.95 | APP (0.46) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL30133577 | 0.95 | APP (0.46) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL420986 | 0.95 | APP (0.46) | APPLMNABLMPTGS1PDE4A | |
| Bromide SCHEMBL31659017 | 0.95 | APP (0.46) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL419968 | 0.95 | APP (0.46) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL754172 | 0.95 | APP (0.46) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL18380848 | 0.95 | APP (0.46) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL754168 | 0.95 | APP (0.46) | APPLMNABLMPTGS1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633609-A1 | LIPID NANOPARTICLES LYOPHILIZATION METHODS AND COMPOSITIONS | Global Life Sciences Solutions Canada ULC (CA) | 2025-10-22 | — | — | EP | claimed |
| WO-2024126423-A1 | LIPID NANOPARTICLES LYOPHILIZATION METHODS AND COMPOSITIONS | Precision NanoSystems ULC (CA) | 2024-06-20 | — | — | WO | claimed |
| CN-117982682-A | Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections | 吉利德科学公司 | 2024-05-07 | — | — | CN | claimed |
| CN-111093627-B | Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections | 吉利德科学公司 | 2024-03-08 | — | — | CN | claimed |
| WO-2023108156-A1 | ZIPRASIDONE FORMULATIONS | BELOTECA, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| CN-115835885-A | Preparation of pharmaceutical composition comprising odaterol and budesonide | 广州谷森制药有限公司 | 2023-03-21 | — | — | CN | claimed |
| EP-4132651-A1 | INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBANUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2023-02-15 | — | — | EP | claimed |
| CN-115362004-A | Inhalation formulations of 1' -cyano-substituted carbon nucleoside analogs | 吉利德科学公司 | 2022-11-18 | — | — | CN | claimed |
| US-20220249395-A1 | PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2022-08-11 | — | — | US | claimed |
| CN-112494444-A | Hydrophilic gel sustained-release tablet containing echinacoside and preparation method and application thereof | 建昌帮药业有限公司 | 2021-03-16 | — | — | CN | claimed |
| EP-1819350-A2 | PHARMACEUTICAL FORMULATIONS CYTIDINE ANALOGS AND DERIVATIVES | SuperGen, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1819227-A1 | PHARMACEUTICAL FORMULATION OF DECITABINE | SuperGen, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006071491-A1 | PHARMACEUTICAL FORMULATION OF DECITABINE | SUPERGEN, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-20060128653-A1 | Pharmaceutical formulation of decitabine | SUPERGEN, INC. | 2006-06-15 | — | — | US | claimed |
| WO-2006063111-A2 | PHARMACEUTICAL FORMULATIONS CYTIDINE ANALOGS AND DERIVATIVES | SUPERGEN, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060128654-A1 | Pharmaceutical formulation of cytidine analogs and derivatives | SUPERGEN, INC. | 2006-06-15 | — | — | US | claimed |
| US-20040053888-A1 | Cyclodextrin-containing pharmaceutical preparation | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-03-18 | — | — | US | claimed |
| EP-1348432-A1 | CYCLODEXTRIN-CONTAINING PHARMACEUTICAL PREPARATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-10-01 | — | — | EP | claimed |
| US-6596706-B1 | For the treatment of circulatory diseases cerebral diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | claimed |
| EP-1029872-A1 | PIPERAZINE-CYCLODEXTRIN COMPLEXES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053888-A1 | Cyclodextrin-containing pharmaceutical preparation | SLCO2B1, RPS27L, SEC23IP | APP 2181/4885LMNA 4571/4885BLM 3702/4885 |
| US-20220249395-A1 | PHARMACEUTICAL FORMULATIONS FOR A LIQUID DOSAGE FORM AND A CONTROLLED RELEASE DOSAGE FORM | HRH4, HRH3, NR4A3 | APP 828/4885LMNA 3657/4885BLM 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.